神经内分泌前列腺癌的当代发病率和死亡率
Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer.
作者信息
Alanee Shaheen, Moore Aaron, Nutt Max, Holland Bradley, Dynda Danuta, El-Zawahry Ahmed, McVary Kevin T
机构信息
Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, U.S.A.
出版信息
Anticancer Res. 2015 Jul;35(7):4145-50.
AIM
The purpose of the study was to provide an update ever the incidence and mortality for neuroendocrine prostate cancer (NEPC) in the United States.
PATIENTS AND METHODS
Using a large national database, we examined changes in age-adjusted incidence (AAIR), mortality rates (MR) and 5-year cancer-specific survival (CSS) for 378 patients diagnosed with NEPC between 1992 and 2011. Analysis was performed for all NEPC and for its two major sub-groups [small cell carcinoma (SCC) and neuroendocrine carcinoma (NEC)].
RESULTS
AAIR of NEPC continues to rise in recent years (2004-2011:+6.8%/year, p>0.05). AAIR of SCC has been increasing significantly by 6.94%/year since 2001 (from 0.470 to 0.582/1,000,000 person years, p<0.05). Overall incidence-based mortality rates for NEPC did not change significantly since 1992 and similar trends were observed for SCC and NEC.
CONCLUSION
The AAIR of SCC is increasing with no change in the MR of NEPC over the past 20 years.
目的
本研究旨在更新美国神经内分泌前列腺癌（NEPC）的发病率和死亡率情况。
患者与方法
利用一个大型国家数据库，我们研究了1992年至2011年间确诊为NEPC的378例患者的年龄调整发病率（AAIR）、死亡率（MR）和5年癌症特异性生存率（CSS）的变化情况。对所有NEPC及其两个主要亚组[小细胞癌（SCC）和神经内分泌癌（NEC）]进行了分析。
结果
近年来NEPC的AAIR持续上升（2004 - 2011年：每年上升6.8%，p>0.05）。自2001年以来，SCC的AAIR以每年6.94%的速度显著上升（从每100万人年0.470例增至0.582例，p<0.05）。自1992年以来，基于发病率的NEPC总体死亡率没有显著变化，SCC和NEC也观察到类似趋势。
结论
在过去20年里，SCC的AAIR在上升，而NEPC的MR没有变化。
Zotero 插件